KRAS and colorectal cancer: A comprehensive characterization of untreated colorectal tumors estimated that 43% of nonhypermutated tumors had KRAS mutations, and these mutations were generally oncogenic activating mutations,11 which means that a large percentage of patients with colorectal cancer are left with few therapeutic options.